Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review

References

• Panou V, Vyberg M, Weinreich U, et al. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev 2015;41(6):486-95
   PubMed Web of Science ®Google Scholar
• Blomberg C, Nilsson J, Holgersson G, et al. Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review. Anticancer Res 2015;35(5):2493-501
   PubMed Web of Science ®Google Scholar
• Faig J, Howard S, Levine EA, et al. Changing pattern in malignant mesothelioma survival. Transl Oncol 2015;8(1):35-9
   PubMed Web of Science ®Google Scholar
• Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev 2015;24(135):115-31
   PubMed Web of Science ®Google Scholar
• Davidson B. Prognostic factors in malignant pleural mesothelioma. Hum Pathol 2015;46(6):789-804
   PubMed Web of Science ®Google Scholar
• Creaney J, Dick IM, Robinson BW. Discovery of new biomarkers for malignant mesothelioma. Curr Pulmonol Reports 2015;4(1):15-21
   PubMedGoogle Scholar
• Kotova S, Wong RM, Cameron RB. New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res 2015;7:51
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-44
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264-9
   PubMed Web of Science ®Google Scholar
• Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2015;16(4):447-56
   PubMed Web of Science ®Google Scholar
• Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26(10):1698-704
   PubMed Web of Science ®Google Scholar
• Gaafar R, Favaretto A, Gregorc V, et al. Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). J Clin Oncol 2015;33:suppl; abstr 7501
   Google Scholar
• Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. J Thorac Oncol 2011;6(11):1950-4
   PubMed Web of Science ®Google Scholar
• Nowak AK, Brown C, Millward MJ, et al. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer 2013;81(3):422-7
   PubMed Web of Science ®Google Scholar
• Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 2012;7(9):1449-56
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Moon J, Garland LL, et al. SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). J Thorac Oncol 2015;10(2):387-91
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009;4(1):97
   PubMed Web of Science ®Google Scholar
• Sørensen JB, Sundstrøm S, Perell K, Thielsen A-K. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007;2(2):147-52
   PubMed Web of Science ®Google Scholar
• Tourkantonis I, Makrilia N, Ralli M, et al. Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. Am J Clin Oncol 2011;34(1):38-42
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015;3(4):301-9
   PubMed Web of Science ®Google Scholar
• de Lima VAB, Sørensen JB. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma. Med Oncol 2015;32(2):1-7
   Web of Science ®Google Scholar
• Dudek AZ, Pang H, Kratzke RA, et al. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol 2012;7(4):755
   PubMed Web of Science ®Google Scholar
• Fennell DA, McDowell C, Busacca S, et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7(9):1466-670
   PubMed Web of Science ®Google Scholar
• Garland LL, Chansky K, Wozniak AJ, et al. Phase II Study of AZD2171 in Patients with Malignant Pleural Mesothelioma: SWOG S0509. J Thor Oncol 2011;6(11):1938
   PubMed Web of Science ®Google Scholar
• Giaccone G, O’Brien M, Byrne M, et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002;38:S19-24
   PubMed Web of Science ®Google Scholar
• Porta C, Zimatore M, Bonomi L, et al. Raltitrexed–oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005;48(3):429-34
   PubMed Web of Science ®Google Scholar
• Cortinovis D, Hollander L, Floriani I, et al. Activity and safety of trabectedin in patients with sarcomatoid/ biphasic malignant pleural mesothelioma (MPM). J Clin Oncol 2015;33(suppl): abstr 7561
   Google Scholar
• Aigner k, Selak E, Sendler A. Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for progressive and pre-treated malignant pleural mesothelioma. J Clin Oncol 2015;33(suppl): abstr 7556
   Google Scholar
• Maron S, Karrison T, Kanteti R, et al. ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II consortium. J Clin Oncol 2015;33(suppl): abstr 7511
   Google Scholar
• Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagine-glycine-arginine–human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010;28(15):2604-11
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Takenoyama M, Hirai F, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2014;19(4):601-6
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second-or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014;84(3):271-4
   PubMed Web of Science ®Google Scholar
• Zucali P, Simonelli M, Michetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012;75(3):360-7
   PubMed Web of Science ®Google Scholar
• Mutlu H, Gündüz Ş, Karaca H, et al. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. Med Oncol 2014;31(8):1-5
   Web of Science ®Google Scholar
• Bearz A, Talamini R, Rossoni G, et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes 2012;5(1):482
   PubMedGoogle Scholar
• Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008;112(7):1555-61
   PubMed Web of Science ®Google Scholar
• Serke M, Bauer T. Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma. ASCO Annual Meeting Proceedings. Berlin, Germany, 2007
   Google Scholar
• La Verde N, Bramati A, Cinquini M, et al. A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM). ASCO Annual Meeting Proceedings. Milan, Italy, 2010
   Google Scholar
• Favoni RE, Florio T. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma. Trends Pharmacol Sci 2011;32(8):463-79
   PubMed Web of Science ®Google Scholar
• Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16(6):923-7
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev Anticancer Ther 2014;14(9):1063-73
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol 2014;92(3):194-207
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. Expert Rev Anticancer Ther 2015;15(1):129-41
   PubMed Web of Science ®Google Scholar
• Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 19 May 2015]
   Google Scholar